This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEB1Q06W_M.jpg
The results show that next-generation Cologuard® met all study endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity.
The company plans to complete the FDA submission by the end of 2023.
“Once approved, next-generation Cologuard will meaningfully enhance the patient experience, and it comes at a critical time – when there are 60 million Americans not up to date with screening,” said CEO Kevin Conroy.
